Poland· PL-100488120
Litfulo
A ritlecitinib product containing ritlecitinibum, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 16 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Ritlecitinib is registered in 16 of 19 countries.
Countries holding a registration under ATC L04AF08 (ritlecitinib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Ritlecitinib · ATC L04AF08
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Ritlecitinibum
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Poland (PL)
- ATC code
- L04AF08
- ATC class
- Ritlecitinib
- Defined daily dose
- 50 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05415062109823
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ritlecitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesLitfuloPfizer Laboratories Div Pfizer Inc
- CzechiaLITFULOPfizer Europe MA EEIG, Bruxelles
- SwitzerlandLitfulo 50 mg, HartkapselnPfizer AG
- SpainLITFULO 50 MG CAPSULAS DURASPfizer Europe Ma Eeig
- FinlandLitfuloPfizer Europe MA EEIG
- FranceLITFULO 50 mg, gélulePFIZER EUROPE MA EEIG (BELGIQUE)
- BelgiumLitfulo 50 mgPfizer Europe MA
- IrelandLitfulo 50 mg hard capsulesPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Litfulo
- Liechtenstein · Litfulo
- Norway · Litfulo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f3ef5c8c-5ee8-4ed2-8e98-715d4fbc7881 GET /v1/drugs/f3ef5c8c-5ee8-4ed2-8e98-715d4fbc7881?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "50 mg",
"packaging": "05415062109823 ¦ Rpz ¦ EU/1/23/1755/002 ¦ 151549\n30 kaps.\nRpz ¦ EU/1/23/1755/001 ¦ 151550\n28 kaps.\nRpz ¦ EU/1/23/1755/003 ¦ 151551\n90 kaps.",
"substance": "Ritlecitinibi tosilas 50 mg",
"common_name": "Ritlecitinibum",
"pl_product_id": "100488120",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about ritlecitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.